

Inventor(s): Stice et al.

Appln. No.: 09/

845,352

Series Code ↑

Serial No. ↑

Filed: May 1, 2001

Hon. Commissioner of Patents
Washington, D.C. 20231

Group Art Unit

1632

Examiner:

D. Crouch

Atty. Dkt.

P 0280611

M#

Client Ref

Appln. Title: Cloned Ungulate Embryos and Animals,
Use of Cells, Tissues and Organs
Thereof for Transplantation Therapies
Including Parkinson's Disease

Sir:

REPLY/AMENDMENT/LETTER

Date: February 6, 2003

This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim

- A. ☐ NOT made
B. ☐ Withdrawn
C. ☐ made herewith
D. ☒ made previously

For B & C
See **Required**
Separate Paper
(Pat-256)

Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity	Additional Fee	Fee Code Lg/Sm
2. Total Effective Claims	**minus 0	0	x \$18/\$9 =	+ \$0	103/203
3. Independent Claims	***minus 0	0	x \$84/\$42 =	+ \$0	102/202
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application)			add	+ \$280/\$140 =	+ \$0 104/204
5. Original due Date: November 6, 2002			<input type="checkbox"/> NONE		
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo) \$110/\$55 = (2 mos) \$410/\$205 = (3 mos) \$930/\$465 = (4 mos) \$1,450/\$725 = (5 mos) \$1,970/\$985 =	+ \$465		115/215 116/216 117/217 118/218 128/228
7. Enter any previous extension fee paid since above original due date and subtract			- \$0		
8.			Extension Fee	+ \$465	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee			+ \$110/\$55	+ \$0	148/248
10. If IDS attached requires Official Fee under Rule 97 (c),			+ \$180	+ \$0	126
or if Rule 97(d) Request			+ \$180		126
11. After-Final Request Fee per rules 129(a) and 17(r)			+ \$750/370	+ \$0	146/246
12. No. of additional inventions for examination per Rule 129(b)			x \$750/375 ea	+ \$0	149/249
13. Request for Continued Examination (RCE)			+ \$750/375	+ \$0	1179/1279
14. Petition fee for				+ \$0	
15.			TOTAL FEE =	\$465	
16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".					
17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.					
18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.					
			PLEASE CHARGE OUR DEP. ACCT		

Our Deposit Account No. 03-3975)

(Our Order No. 015837 0280611

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Samir Elamrani

Reg. No. 43601

P.O. Box 10500
McLean, VA 22102
Tel: (703) 905-2000

Sig:

Charles Rami for
Samir Elamrani

Fax: (703) 905-2500
Tel: (703) 905-2064

Atty/Sec: SE/af

NOTE: File this cover sheet in duplicate with PTO receipt (PAT-103A) and attachments



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Steven L. Stice et al.

Group Art Unit: 1632

Application Serial No. 09/845,352

Examiner: D. Crouch

Filed: May 01, 2001

Title: CLONED UNGULATE EMBRYOS AND ANIMALS, USE OF CELLS, TISSUES AND ORGANS THEREOF FOR TRANSPLANTATION THERAPIES INCLUDING PARKINSON'S DISEASE

TECH CENTER 1600/2900

FEB 10 2003

RECEIVED

2/10/03

* * * * *

RESPONSE TO OFFICIAL ACTION

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Official Action dated August 6, 2002, kindly enter the following amendments and remarks.

In the Claims

Please cancel claims 7-14, 26-32, and 36-46, and amend claims 1, 6, 18, 19, 25, 33, and 47 as shown below:

a¹ 1. (Amended) A method of treating a patient with Parkinson's disease or a Parkinson's-type disease comprising administering to or transplanting into said patient a therapeutically effective amount of dopamine cells obtained from a cloned ungulate.

a² 6. (Amended) The method of Claim 5, wherein said cells are fetal dopamine neuronal cells.

a³ 15. (Amended) A method of treating a patient with Parkinson's disease or a Parkinson's-type disease comprising administering to or transplanting into said patient a therapeutically effective amount of cloned, transgenic fetal dopamine cells obtained from a cloned ungulate.